<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02706938</url>
  </required_header>
  <id_info>
    <org_study_id>IBELGA</org_study_id>
    <nct_id>NCT02706938</nct_id>
  </id_info>
  <brief_title>Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease</brief_title>
  <acronym>IBELGA</acronym>
  <official_title>Impact of Head of Bed Elevation in Symptoms of Patients With Gastroesophageal Reflux Disease: a Randomized Single-blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Nacional de Colombia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universidad Nacional de Colombia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND: Gastroesophageal reflux disease is a very frequent clinical condition and
      nocturnal symptoms are a cause of quality of life impairment, poor sleep quality and
      absenteeism. Head of bed elevation, as a low-cost non pharmacologic anti-reflux treatment is
      nowadays recommended, but its clinical impact in patients with nocturnal symptoms remains
      unknown due to inconsistent results and methodological limitations among different clinical
      trials, most of which were performed before the widespread use of proton pump inhibitors in
      clinical practice.

      HYPOTHESIS: Head of bed elevation is a useful treatment for patients with gastroesophageal
      reflux disease and nocturnal symptoms, and has a positive impact in quality of life in these
      patients.

      STUDY OBJECTIVE: To assess the effectiveness of head of bed elevation for treatment of
      patients with gastroesophageal reflux disease and nocturnal symptoms, and to determine the
      impact of this intervention in quality of life of these patients.

      METHODS: Randomized single-blind single-centre controlled clinical trial with a 2x2
      cross-over design. A sample of 42 patients attending to the outpatient gastroenterology unit
      at Clínica Fundadores in Bogotá city, who met the inclusion criteria and had no exclusion
      criteria were selected to participate. Included patients were randomized to raise the head of
      bed with standard 20 cm-height wooden blocks or to sleep without bed inclination during the
      first 6 week period. After a 2 week washout period, allocation was crossed and participants
      were followed again during a second 6 week period. During the trial, every patient received
      standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate. After
      allocation concealment, the researchers in charge of statistical analysis and reporting
      results were blinded for the non pharmacological intervention under study. Primary outcome
      was a significant symptom change according to Reflux Disease Questionnaire (RDQ) validated
      form. Secondary outcomes include impact on quality of life according to Short Form 36 (SF-36)
      validated questionnaire, patient preference and adverse events of non-pharmacological
      intervention. Statistical analysis was carried out with STATA 13.0 (Special Edition) for
      Windows. Differences with a p&lt;0,05 were accepted as statistically significant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROBLEM STATEMENT

      Gastroesophageal reflux disease (GERD) is a clinical condition characterized by troublesome
      symptoms and medical complications as a result of reflux of gastric contents into the
      esophagus. GERD is diagnosed in 4% of primary care outpatient visits and the disease
      prevalence in Latin-America reaches 12-31%. Nocturnal symptoms have been found in 74% of
      patients with GERD and are a cause of significant quality of life impairment, when compared
      with general population and patients with GERD and daytime-only symptoms. Sleep interference
      secondary to nocturnal retrosternal burning has been associated to lower work productivity,
      even in patients being treated with proton pump inhibitors (PPI). Due to several
      physiological factors such as lack of conscious perception of symptoms, reduced salivation
      and a lower frequency of nocturnal swallowing, a significantly longer acid exposure overnight
      has been associated to the emergence of complications like esophagitis, more extra-esophageal
      symptoms and other illnesses such as asthma.

      As a low-cost non pharmacological anti-reflux treatment for GERD, head of bed elevation (HBE)
      is nowadays a moderate-strength recommendation with low level of evidence. Clinical impact of
      this measure in patients with night-time symptoms remains unknown, due to inconsistent
      results and methodological limitations among different clinical trials; most of which were
      performed before the widespread use of proton pump inhibitors in clinical practice. Evidence
      from several non-randomized studies suggest that HBE could reduce esophageal acid exposure
      time and could decrease GERD symptoms; however, another study found no significant
      differences in those same outcomes. On the other hand, all randomized controlled clinical
      trials published this far show inconsistent results. A study published before widely accepted
      clinical use of PPI, revealed significant clinical and endoscopic improvement with HBE in
      patients with GERD and grade C-D esophagitis, when compared to controls. In contrast, a
      multi-centre clinical trial found no difference in symptom score or antacid use among groups
      allocated to HBE and control group. All cited studies have methodological limitations and
      heterogeneity in outcome assessments, which makes difficult conducting a meta-analysis with
      these data. No published studies evaluating impact of HBE in quality of life or work
      productivity were found.

      SAMPLE SIZE CALCULATION

      Sample size was estimated based on the hypothesis that HBE would produce a difference of at
      least 10% in RDQ and SF-36 scores. Effect size (Cohen d) was calculated as 0,49, keeping in
      mind an RDQ mean and standard deviation of 3,3±1,0 previously found in Spanish population
      with symptomatic GERD. An SF-36 mean and standard deviation of 56,9±20,3 reported in Italian
      population in medical therapy with PPI were also taken into account. The minimally important
      difference selection was chosen based on the assumption that any difference smaller than 10%
      would have no clinical relevance. Based on this data, 14 patients per group would yield a
      power greater than 80% for detection of a minimally important difference as large as or
      larger than 0,6 points in RDQ questionnaire (range: 1 to 6) and 10 points in SF-36
      questionnaire (range: 0 to 100), when using a paired t test. For a complementary analysis of
      this trial, by using a McNemar test, effect size was recalculated based on published clinical
      trial data from pre-omeprazole era, according to which 58,8% and 28,6% of patients assigned
      to placebo improved gastroesophageal reflux symptoms with and without 20 cm HBE,
      respectively. Based on this data, and maintaining a statistical power of 80%, required sample
      size was adjusted to a total of 34 patients. G*Power 3.1.9.2 software (Universität
      Düsseldorf, Düsseldorf, Germany). Finally, estimated sample size was incremented by 20% to
      avoid that eventual losses of follow-up may alter study power. Therefore, final sample size
      was 42 patients, 21 patients per group.

      DESIGN AND CARVING OF WOODEN PRISMS

      84 prisms of withered pine tree wood with dimensions 20x18x18 cm were carved from 9 logs of
      300x20x20 cm at Aserrío San Ignacio Ltda. production plant, located in Soacha, Cundinamarca.
      Given it is an industrial process of chainsaw cutting and wood planing, a quality control was
      implemented consisting of verification of prism stability while lying on the floor, and the
      mean height in millimeters of every prism will also be measured and registered. Unsteady
      products or those with atypical mean heights, defined as a height either exceeding percentile
      75 + 1,5 times interquartile range or below percentile 25 - 1,5 times interquartile range,
      will be discarded and not used during the study. After exclusion of defective prisms,42
      groups of wooden prism pairs according to mean height in millimeters were formed and every
      group was given a random digit generated by computer. Afterwards, every random digit of prism
      groups was sequentially assigned to a consecutive HBE-allocated patient number, in such a way
      that every consecutive patient number (among those allocated to HBE) will be linked randomly
      to a preset known prism height. This additional randomization procedure involving prisms
      according to their mean height, is planned due to the impossibility to guarantee that prism
      height will be identical with a precision of ±1 mm, keeping in mind that products will be cut
      with chainsaw and will be planed as part of an industrial process. After quality control
      process, mean prism height was found to be a non-normal distributed variable (W:0,908; critic
      W: 0,979; p: 0,000000), and after applying predetermined exclusion rules for atypical data, 2
      pairs of wooden prisms were discarded.

      RANDOMIZATION

      A random binomial number list (zeroes and ones) will be generated with the statistical
      software STATA SE 13.0 for Windows and the list will be used for allocation of 42 patients
      between intervention and control groups in a 1:1 proportion. Each one of the 42 pairs of
      wooden prisms will be marked with a consecutive number coming from an HBE-allocated patient
      and the prisms will be stored keeping the marked number out of reach from the sight of the
      researcher in charge of patient recruiting.

      Patients that meet the inclusion criteria, have no exclusion criteria and who give written
      informed consent, will be assigned a consecutive number during their outpatient visit
      according to their order of inclusion in the trial. These participants will be randomized to
      either HBE or control group in the moment that a member of the research team verifies, among
      the stored prisms, the existence of a prism pair marked with the same number as the
      consecutive number assigned to the patient. In the case that this pair does exist, then the
      patient will take home that pair of wooden prisms and use them during the first period of the
      trial according to spoken and written instructions to be given at that moment. On the
      contrary, if a pair of wooden prisms marked with the same consecutive number as the patient,
      does not exist, then it will be understood that the study participant has been allocated to
      control group during the first period of the trial. The member of the research team who
      verifies the storehouse of wooden prisms will not be in charge of confirming inclusion and
      exclusion criteria and will not assign consecutive numbers to patients during outpatient
      visits.

      ALLOCATION CONCEALMENT

      The researcher in charge of confirming inclusion and exclusion criteria, fulfilling the Basic
      Data Formulary and providing the patient with the Informed Consent Format, will not be aware
      of the allocation sequence order until these 3 documents have been applied to the participant
      and a consecutive number has been generated according to their order of inclusion in the
      trial. After that, a member of the research team in the prism storehouse will verify the
      existence of a prism pair marked with the same number as the consecutive number assigned to
      the patient, and only in that point allocation status of the participant will be known.

      CROSS-OVER

      After allocation has been completed, patients in the intervention group will receive a pair
      of numbered wooden prisms with dimensions 20x18x18 cm along with written instructions about
      the correct use of the intervention. The patient must sleep with HBE during 6 weeks and both
      RDQ and SF-36 questionnaires will be applied again at the end of this first period while the
      participant is still sleeping with HBE. Afterwards, a washout 2 week period follows in which
      the participant sleeping with HBE will stop using it and will return the pair of wooden
      prisms to the researchers. After washout period has ended and both RDQ and SF-36
      questionnaires have been applied again, patients allocated to the control group during the
      first period of the study will receive a random pair of prisms and will be instructed to use
      the prisms for sleeping with HBE during a second period of 6 weeks. Meanwhile, participants
      initially allocated to the HBE group will be followed as a control group in this second
      period of the study.

      FOLLOW-UP

      After participant allocation, telephonic follow up will be made during both periods of the
      trial with a frequency that is dependent on the intervention group of the patient in that
      period. Participants in the HBE group will be called weekly for 2 weeks, and then will be
      called biweekly for a month, until each period of 6 weeks has ended. In contrast, patients in
      the control group will be called every three weeks along each period. With the purpose of
      verifying both HBE adherence and correct use of wooden prisms, every participant will be
      asked to send a photograph of the bed head legs during the follow-up telephone call. The
      photograph will be received by the researcher via e-mail or smart-phone and will be encoded
      and saved in a hard disk. At the end of the first period, RDQ and SF-36 questionnaires will
      be applied and researchers will store the returned prisms during washout period. When washout
      period has ended, RDQ and SF-36 questionnaires will be applied again in order to be sure of
      the absence of any carry-over effect in the group initially allocated to HBE. Finally at week
      14, RDQ, SF-36 and Patient Preference questionnaires will be administered to complete study
      ending outcome assessments.

      STATISTIC ANALYSIS PLAN

      Quantitative and qualitative variables collected with Basic Data Format, RDQ, SF-36 and
      Patient Preference questionnaires will be typed in a Microsoft Excel 2007 database.
      Intervention groups will be masked with an alphabetical code provided by an independent
      collaborator who will not be involved with data analysis or report writing. For statistical
      processing, database will be imported into STATA SE 13.0 for Windows and descriptive
      statistics will be generated for each variable. Statistically significant differences will be
      searched for categorical data using the Chi-square test and normality will be tested for
      numerical continuous variables using the Shapiro-Wilk test. For normally distributed
      continuous variables, statistically significant differences will be searched for by using
      unpaired Student's t test. Alternatively, for not normally distributed variables a Wilcoxon
      signed rank test will be applied. For complementary processing of primary outcome and
      secondary outcome quality of life, score difference between periods will be transformed into
      a binomial variable and a McNemar test will be applied. Differences with one-tail p&lt;0,05 will
      be accepted as statistically significant. Subgroup analysis will explore differences
      stratified according to age group, sex, ethnic group, BMI, comorbidities, cups of coffee per
      day, pharmacological adherence, and length and severity of symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 8, 2016</start_date>
  <completion_date type="Actual">November 15, 2017</completion_date>
  <primary_completion_date type="Actual">November 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized single-blind single-centre controlled clinical trial with a 2x2 cross-over design.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Because HBE is not susceptible to double-blinding, patients allocated to the intervention group will always be aware of the group they belong to. However, the researcher in charge of statistical analysis of data and writing the results report will work with random-generated alphabetical group codes for masking the intervention in each one of the periods of the trial.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention</measure>
    <time_frame>Primary outcome will be assessed at baseline and 6 weeks after starting each period</time_frame>
    <description>Change in Reflux Disease Questionnaire Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 6, with a higher punctuation meaning a worse outcome. Symptom change of ≥ 0,6 points from baseline was considered clinically relevant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of Life as Assessed by Short Form 36 Questionnaire, Administered at Baseline and 6 Weeks After Each Intervention</measure>
    <time_frame>Secondary outcome will be assessed at baseline and 6 weeks after starting each period</time_frame>
    <description>Change in Short Form 36 Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 100, with a higher punctuation meaning a better outcome. Quality of life change of ≥ 10 points from baseline was considered clinically relevant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Preference</measure>
    <time_frame>Secondary outcome will be assessed 14 weeks after starting the trial</time_frame>
    <description>Percentage of patients who preferred head of bed elevation after trial ending</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Head of bed elevation - Control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control - Head of bed elevation</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Head of bed elevation</intervention_name>
    <description>Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed</description>
    <arm_group_label>Control - Head of bed elevation</arm_group_label>
    <arm_group_label>Head of bed elevation - Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
    <arm_group_label>Control - Head of bed elevation</arm_group_label>
    <arm_group_label>Head of bed elevation - Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Esophageal erosions

          -  Retrosternal pyrosis lasting ≥ 3 months

          -  Pyrosis and/or regurgitation with a frequency ≥ 3 nights per week

          -  GERD-associated sleep disturbance (insomnia, poor sleep quality) lasting ≥ 1 month

          -  GERD-associated sleep disturbance (insomnia, poor sleep quality) with a frequency ≥ 3
             nights per week

        Exclusion Criteria:

          -  Non-erosive gastroesophageal reflux disease (NERD)

          -  Peptic ulcer

          -  History of upper gastrointestinal surgery (except for cholecystectomy)

          -  Lactating or pregnant women

          -  Nighttime shift workers (12 am to 6 am)

          -  Obstructive sleep apnea hypopnea syndrome

          -  Chronic obstructive pulmonary disease

          -  Patients with nocturnal supplementary oxygen requirement

          -  Orthopnea

          -  Restless legs syndrome

          -  Patients consuming more than 3 cups of coffee per day

          -  Patients planning to travel beyond 3 time zones during study

          -  Patients being treated with sleep medication (e.g. anxiolytics, antihistamines,
             benzodiazepines) for less than 3 months

          -  Patients being treated with sleep medication (e.g. anxiolytics, antihistamines,
             benzodiazepines), when suspension or dose modification of this drugs is being planned
             during the study course
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ivan M Villamil Morales, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad Nacional de Colombia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>William A Otero Regino, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Universidad Nacional de Colombia, Clínica Fundadores</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Fundadores</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <reference>
    <citation>Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R; Global Consensus Group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006 Aug;101(8):1900-20; quiz 1943.</citation>
    <PMID>16928254</PMID>
  </reference>
  <reference>
    <citation>Vakil N, Malfertheiner P, Salis G, Flook N, Hongo M. An international primary care survey of GERD terminology and guidelines. Dig Dis. 2008;26(3):231-6. doi: 10.1159/000121352. Epub 2008 May 6.</citation>
    <PMID>18463441</PMID>
  </reference>
  <reference>
    <citation>Salis G. [Systematic review: Epidemiology of gastroesophageal reflux disease in Latin America]. Acta Gastroenterol Latinoam. 2011 Mar;41(1):60-9. Spanish.</citation>
    <PMID>21539070</PMID>
  </reference>
  <reference>
    <citation>Farup C, Kleinman L, Sloan S, Ganoczy D, Chee E, Lee C, Revicki D. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch Intern Med. 2001 Jan 8;161(1):45-52.</citation>
    <PMID>11146697</PMID>
  </reference>
  <reference>
    <citation>Dean BB, Crawley JA, Schmitt CM, Wong J, Ofman JJ. The burden of illness of gastro-oesophageal reflux disease: impact on work productivity. Aliment Pharmacol Ther. 2003 May 15;17(10):1309-17.</citation>
    <PMID>12755844</PMID>
  </reference>
  <reference>
    <citation>Gross M, Beckenbauer U, Burkowitz J, Walther H, Brueggenjuergen B. Impact of gastro-oesophageal reflux disease on work productivity despite therapy with proton pump inhibitors in Germany. Eur J Med Res. 2010 Mar 30;15(3):124-30.</citation>
    <PMID>20452898</PMID>
  </reference>
  <reference>
    <citation>Orr WC, Heading R, Johnson LF, Kryger M. Review article: sleep and its relationship to gastro-oesophageal reflux. Aliment Pharmacol Ther. 2004 Dec;20 Suppl 9:39-46. Review.</citation>
    <PMID>15527463</PMID>
  </reference>
  <reference>
    <citation>Orr WC, Allen ML, Robinson M. The pattern of nocturnal and diurnal esophageal acid exposure in the pathogenesis of erosive mucosal damage. Am J Gastroenterol. 1994 Apr;89(4):509-12.</citation>
    <PMID>8147351</PMID>
  </reference>
  <reference>
    <citation>Adachi K, Fujishiro H, Katsube T, Yuki M, Ono M, Kawamura A, Rumi MA, Watanabe M, Kinoshita Y. Predominant nocturnal acid reflux in patients with Los Angeles grade C and D reflux esophagitis. J Gastroenterol Hepatol. 2001 Nov;16(11):1191-6.</citation>
    <PMID>11903734</PMID>
  </reference>
  <reference>
    <citation>López-Alvarenga JC, Orr W, Vargas-Romero JA, Remes-Troche JM, Morales-Arámbula M, Soto-Pérez JC, Mateos-Pérez G, Sobrino-Cossío S, Teramoto-Matsubara O, López-Colombo A, Orozco-Gamiz A, Saez-Ríos A, Arellano-Plancarte A, Chiu-Ugalde J, Tholen A, Horbach S, Lundberg L, Fass R. Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group. J Neurogastroenterol Motil. 2014 Jan;20(1):64-73. doi: 10.5056/jnm.2014.20.1.64. Epub 2013 Dec 30.</citation>
    <PMID>24466446</PMID>
  </reference>
  <reference>
    <citation>Gislason T, Janson C, Vermeire P, Plaschke P, Björnsson E, Gislason D, Boman G. Respiratory symptoms and nocturnal gastroesophageal reflux: a population-based study of young adults in three European countries. Chest. 2002 Jan;121(1):158-63.</citation>
    <PMID>11796445</PMID>
  </reference>
  <reference>
    <citation>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329. doi: 10.1038/ajg.2012.444. Epub 2013 Feb 19. Erratum in: Am J Gastroenterol. 2013 Oct;108(10):1672.</citation>
    <PMID>23419381</PMID>
  </reference>
  <reference>
    <citation>Federação Brasileira de Gastroenterologia; Sociedade Brasileira de Endoscopia Digestiva; Colégio Brasileiro de Cirurgia Digestiva; Sociedade Brasileira de Pneumologia; Associação Brasileira de Otorrinolaringologia; Cirurgia Cérvico-Facial. [Gastroesophageal reflux disease: non-pharmacological treatment]. Rev Assoc Med Bras (1992). 2012 Jan-Feb;58(1):18-24; quiz 25. Portuguese.</citation>
    <PMID>22392311</PMID>
  </reference>
  <reference>
    <citation>Internal Clinical Guidelines Team (UK). Dyspepsia and Gastro-Oesophageal Reflux Disease: Investigation and Management of Dyspepsia, Symptoms Suggestive of Gastro-Oesophageal Reflux Disease, or Both. London: National Institute for Health and Care Excellence (UK); 2014 Sep.</citation>
    <PMID>25340236</PMID>
  </reference>
  <reference>
    <citation>Gastroenterological Society of Australia (GESA). Reflux disease: Gastrooesophageal reflux disease in adults. Victoria: GESA 2011. Available from: http://www.gesa.org.au/files/editor_upload/File/Professional/Reflux_Disease.pdf (Accessed Dic, 2014).</citation>
  </reference>
  <reference>
    <citation>Stanciu C, Bennett JR. Effects of posture on gastro-oesophageal reflux. Digestion. 1977 Feb;15(2):104-9.</citation>
    <PMID>14044</PMID>
  </reference>
  <reference>
    <citation>Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig Dis Sci. 1981 Aug;26(8):673-80.</citation>
    <PMID>7261830</PMID>
  </reference>
  <reference>
    <citation>Khan BA, Sodhi JS, Zargar SA, Javid G, Yattoo GN, Shah A, Gulzar GM, Khan MA. Effect of bed head elevation during sleep in symptomatic patients of nocturnal gastroesophageal reflux. J Gastroenterol Hepatol. 2012 Jun;27(6):1078-82. doi: 10.1111/j.1440-1746.2011.06968.x.</citation>
    <PMID>22098332</PMID>
  </reference>
  <reference>
    <citation>Hamilton JW, Boisen RJ, Yamamoto DT, Wagner JL, Reichelderfer M. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci. 1988 May;33(5):518-22.</citation>
    <PMID>3359906</PMID>
  </reference>
  <reference>
    <citation>Harvey RF, Gordon PC, Hadley N, Long DE, Gill TR, Macpherson RI, Beats BC, Tottle AJ. Effects of sleeping with the bed-head raised and of ranitidine in patients with severe peptic oesophagitis. Lancet. 1987 Nov 21;2(8569):1200-3.</citation>
    <PMID>2890820</PMID>
  </reference>
  <reference>
    <citation>Pollmann H, Zillessen E, Pohl J, Rosemeyer D, Abucar A, Armbrecht U, Bornhofen B, Herz R. [Effect of elevated head position in bed in therapy of gastroesophageal reflux]. Z Gastroenterol. 1996 Jun;34 Suppl 2:93-9. German.</citation>
    <PMID>8767437</PMID>
  </reference>
  <reference>
    <citation>Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med. 2006 May 8;166(9):965-71. Review.</citation>
    <PMID>16682569</PMID>
  </reference>
  <reference>
    <citation>Gerson LB, Fass R. A systematic review of the definitions, prevalence, and response to treatment of nocturnal gastroesophageal reflux disease. Clin Gastroenterol Hepatol. 2009 Apr;7(4):372-8; quiz 367. doi: 10.1016/j.cgh.2008.11.021. Epub 2008 Dec 3. Review.</citation>
    <PMID>19111949</PMID>
  </reference>
  <reference>
    <citation>Nuevo J, Tafalla M, Zapardiel J. [Validation of the Reflux Disease Questionnaire (RDQ) and Gastrointestinal Impact Scale (GIS) in patients with gastroesophageal reflux disease in the Spanish population]. Gastroenterol Hepatol. 2009 Apr;32(4):264-73. doi: 10.1016/j.gastrohep.2008.12.004. Epub 2009 Apr 16. Spanish.</citation>
    <PMID>19371971</PMID>
  </reference>
  <reference>
    <citation>Rossetti G, Limongelli P, Cimmino M, Napoletano D, Bondanese MC, Romano G, Pratilas M, Guerriero L, Orlando F, Conzo G, Amato B, Docimo G, Tolone S, Brusciano L, Docimo L, Fei L. Outcome of medical and surgical therapy of GERD: predictive role of quality of life scores and instrumental evaluation. Int J Surg. 2014;12 Suppl 1:S112-6. doi: 10.1016/j.ijsu.2014.05.034. Epub 2014 Jun 2.</citation>
    <PMID>24946311</PMID>
  </reference>
  <reference>
    <citation>Uniform requirements for manuscripts submitted to biomedical journals: Writing and editing for biomedical publication. J Pharmacol Pharmacother. 2010 Jan;1(1):42-58.</citation>
    <PMID>21808590</PMID>
  </reference>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 11, 2016</study_first_posted>
  <results_first_submitted>November 14, 2018</results_first_submitted>
  <results_first_submitted_qc>March 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 24, 2019</results_first_posted>
  <last_update_submitted>March 29, 2019</last_update_submitted>
  <last_update_submitted_qc>March 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastroesophageal reflux disease</keyword>
  <keyword>Head of bed elevation</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Nocturnal symptoms</keyword>
  <keyword>Lifestyle measures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Esophagitis, Peptic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>Informed Consent Form</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://drive.google.com/file/d/0B6Uam9x9PtiiZzRVZE5wQmhIV1E/view?usp=sharing</doc_url>
      <doc_comment>Informed Consent Form</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>Basic Data Formulary</doc_id>
      <doc_type>Basic Data Formulary</doc_type>
      <doc_url>https://drive.google.com/file/d/0B6Uam9x9PtiiVS1GUWl6Q0pFWWs/view?usp=sharing</doc_url>
      <doc_comment>Formulary for gathering basic variables of each participant</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>SF-36 questionnaire</doc_id>
      <doc_type>SF-36 questionnaire</doc_type>
      <doc_url>https://drive.google.com/file/d/0B6Uam9x9PtiiVFVTY2dUVDA2UkE/view?usp=sharing</doc_url>
      <doc_comment>Questionnaire for assessing secondary outcome</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>RDQ questionnaire</doc_id>
      <doc_type>RDQ questionnaire</doc_type>
      <doc_url>https://drive.google.com/file/d/0B6Uam9x9PtiieExLaGJyZDVVV00/view?usp=sharing</doc_url>
      <doc_comment>Questionnaire for assessing primary outcome</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>Instruction for the patient</doc_id>
      <doc_type>Instructions for the patient</doc_type>
      <doc_url>https://drive.google.com/file/d/0B6Uam9x9PtiiMVJDbVhLVFY1bnc/view?usp=sharing</doc_url>
      <doc_comment>Written instructions for the patient about how to use wooden prisms.</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>Clinical Trial Protocol</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://drive.google.com/open?id=0B6Uam9x9PtiiV2xUcDBKU3RHYU0</doc_url>
    </study_doc>
  </study_docs>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol, Statistical Analysis Plan, and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02706938/Prot_SAP_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted at the outpatient visit of the Gastroenterology, Digestive endoscopy and Liver Diseases Unit in Clínica Fundadores, Bogotá, Colombia. A search for eligible patients was also conducted by using a Local Endoscopy Database with a time frame from 2014 to 2016, and patients with esophagitis were contacted by telephone.</recruitment_details>
      <pre_assignment_details>1082 out of 1147 potentially eligible patients were excluded prior to randomization. 941 patients did not meet the inclusion criteria and 105 patients had at least one exclusion criteria. 36 patients declined their participation before starting the clinical trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Head of Bed Elevation - Control</title>
          <description>Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
Head of bed elevation: Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
        </group>
        <group group_id="P2">
          <title>Control - Head of Bed Elevation</title>
          <description>Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
Head of bed elevation: Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Period, 6 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="33"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Period, 6 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21">Only data from 20 patients were finally analyzed because of missing data.</participants>
                <participants group_id="P2" count="21">Only data from 19 patients were finally analyzed because of missing data.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Head of Bed Elevation - Control</title>
          <description>Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks. After a washout 2 week period, participants will sleep in a bed without inclination for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
Head of bed elevation: Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
        </group>
        <group group_id="B2">
          <title>Control - Head of Bed Elevation</title>
          <description>Participants will sleep in a bed without inclination during a first period of 6 weeks. After a washout 2 week period, participants will sleep with head of bed raised with standard 20 cm-height wooden blocks for a second period of 6 weeks. During the trial, every patient will receive standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
Head of bed elevation: Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="33"/>
            <count group_id="B3" value="65"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="8.0"/>
                    <measurement group_id="B2" value="54" spread="12.6"/>
                    <measurement group_id="B3" value="55.5" spread="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Los Angeles Classification</title>
          <description>Participants were graded according to the extension of endoscopically confirmed mucosal breaks in the esophagus. Letters from A to D were used for grading, with A meaning a smaller mucosal tear, and D meaning a bigger mucosal tear.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Grade A Esophagitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="53"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade B Esophagitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade C Esophagitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Grade D Esophagitis</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GERD diagnosis</title>
          <description>Self reported years since gastroesophageal reflux disease diagnosis</description>
          <units>Years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="B2" value="5" lower_limit="2" upper_limit="10"/>
                    <measurement group_id="B3" value="5" lower_limit="2" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GERD-associated sleep disturbance</title>
          <units>Nights per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="B2" value="4" lower_limit="3" upper_limit="4"/>
                    <measurement group_id="B3" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Proton pump inhibitor use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Omeprazole use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Esomeprazole use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lansoprazole use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sodium Alginate use</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>GERD therapy adherence</title>
          <description>The values in the table refer to those participants who were considered having &quot;adherence&quot; to their therapy by means of Morinsky-Green-Levine test.</description>
          <population>Row population differs from the Overall because of missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="26"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="56"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>OTC antacid use</title>
          <description>Over-the-counter antacid use</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of pillows</title>
          <units>pillows</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B3" value="2" lower_limit="1" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sleep medication</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Nocturia</title>
          <description>The need to wake at night one or more times for voiding</description>
          <units>Nights per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" lower_limit="0.5" upper_limit="7"/>
                    <measurement group_id="B2" value="6" lower_limit="1" upper_limit="7"/>
                    <measurement group_id="B3" value="4" lower_limit="1" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cups of coffee</title>
          <description>Patients reported the number of cups of coffee they usually drink daily, taking into account a standard cup of 195 mL.</description>
          <units>cup</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="B2" value="1" lower_limit="0" upper_limit="2"/>
                    <measurement group_id="B3" value="1" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <description>Self-reported weight</description>
          <population>This row populattion differs from the overall because of missed data</population>
          <units>Kilogram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" spread="12.7"/>
                    <measurement group_id="B2" value="61.8" spread="9.5"/>
                    <measurement group_id="B3" value="64.6" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <description>Self-reported height</description>
          <population>This row populattion differs from the overall because of missed data</population>
          <units>centimeter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="161.4" spread="9.6"/>
                    <measurement group_id="B2" value="159.4" spread="5.7"/>
                    <measurement group_id="B3" value="160.4" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <population>This row populattion differs from the overall because of missed data</population>
          <units>Kilogram/square meter</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.5" lower_limit="22.9" upper_limit="27.8"/>
                    <measurement group_id="B2" value="24.9" lower_limit="22.7" upper_limit="25.9"/>
                    <measurement group_id="B3" value="24.6" lower_limit="22.8" upper_limit="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Basal RDQ score</title>
          <description>Participants were graded according to presence and intensity of reflux symptoms. Reflux Disease Questionnaire (RDQ) was used as a scale with a range from 0 to 6 points, being 0 abscence of symptoms, and 6 the worst intensity of reflux symptoms.</description>
          <population>This row populattion differs from the overall because of missed data</population>
          <units>Score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="32"/>
                    <count group_id="B3" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.8" spread="1.01"/>
                    <measurement group_id="B2" value="4" spread="1.08"/>
                    <measurement group_id="B3" value="3.9" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 score</title>
          <description>Participants were graded according to a measure of their overall quality of life. Short Form 36 (SF-36) was used as a scale with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>This row populattion differs from the overall because of missed data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="19.9"/>
                    <measurement group_id="B2" value="48.8" spread="21.4"/>
                    <measurement group_id="B3" value="51.3" spread="20.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 Physical Function domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account their physical performance. Short Form 36 Physical Function Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>This row populattion differs from the overall because of missed data</population>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" lower_limit="45" upper_limit="80"/>
                    <measurement group_id="B2" value="55" lower_limit="35" upper_limit="80"/>
                    <measurement group_id="B3" value="60" lower_limit="35" upper_limit="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 Physical Role domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account if they had role limitations due to physical problems. Short Form 36 Physical Role Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>This row populattion differs from the overall because of missed data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" spread="45.7"/>
                    <measurement group_id="B2" value="32.2" spread="42.4"/>
                    <measurement group_id="B3" value="40.6" spread="44.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 Bodily Pain domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account their bodily pain. Short Form 36 Bodily Pain Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>This row populattion differs from the overall because of missed data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.8" spread="25"/>
                    <measurement group_id="B2" value="40.9" spread="26.5"/>
                    <measurement group_id="B3" value="42.3" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 General Health Domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account their general health. Short Form 36 General Health Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>Row population differs from the Overall because of missing data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.8" spread="16.5"/>
                    <measurement group_id="B2" value="49.5" spread="18.2"/>
                    <measurement group_id="B3" value="50.6" spread="17.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 Vitality Domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account their vitality. Short Form 36 Vitality Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>Row population differs from the Overall because of missing data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="15.8"/>
                    <measurement group_id="B2" value="45.5" spread="20.7"/>
                    <measurement group_id="B3" value="48.2" spread="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 Social Function Domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account their social performance. Short Form 36 Social Function Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>Row population differs from the Overall because of missing data</population>
          <units>scores on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.5" lower_limit="55" upper_limit="90"/>
                    <measurement group_id="B2" value="67.5" lower_limit="42.5" upper_limit="87.5"/>
                    <measurement group_id="B3" value="67.5" lower_limit="55" upper_limit="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 Emotional Role domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account if they had role limitations due to emotional problems. Short Form 36 Emotional Role Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>Row population differs from the Overall because of missing data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60" spread="44.1"/>
                    <measurement group_id="B2" value="57" spread="45.7"/>
                    <measurement group_id="B3" value="58.5" spread="44.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 Mental Health domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account their mental health. Short Form 36 Mental Health Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent, being 0 the worst quality of life, and 100 the best quality of life.</description>
          <population>Row population differs from the Overall because of missing data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.8" spread="18"/>
                    <measurement group_id="B2" value="57.9" spread="22.8"/>
                    <measurement group_id="B3" value="59.3" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SF-36 Transition domain</title>
          <description>Participants were graded according to a measure of their quality of life, having into account if they felt a transition of their general health during the previous year. Short Form 36 Transition Domain, a sub-scale of SF-36 was used with a range from 0 to 100 percent. Lower percent values mean that participant believes general health is much worse now than one year ago, and higher percent values mean that participant believes general health is much better now than one year ago.</description>
          <population>Row population differs from the Overall because of missing data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="31"/>
                    <count group_id="B3" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" spread="19"/>
                    <measurement group_id="B2" value="37.9" spread="22.2"/>
                    <measurement group_id="B3" value="41.4" spread="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Comorbidities</title>
          <description>Number of other chronic illnesses</description>
          <units>Comorbidity</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" lower_limit="1" upper_limit="2"/>
                    <measurement group_id="B2" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="B3" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arterial hypertension</title>
          <description>Previous diagnosis of chronic arterial hypertension</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Varicose veins</title>
          <description>Previous diagnosis of varicose veins in the legs</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hypothyroidism</title>
          <description>Previous diagnosis of hypothyroidism</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fibromyalgia</title>
          <description>Previous diagnosis of fibromyalgia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arthrosis</title>
          <description>Previous diagnosis of arthrosis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Irritable bowel syndrome</title>
          <description>Previous diagnosis of irritable bowel syndrome</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Depressive disorder</title>
          <description>Previous diagnosis of depressive disorder</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Obesity</title>
          <description>Participants with a body mass index of 30 or greater</description>
          <population>Row population differs from the Overall because of missing data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="31"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="64"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Anxiety disorder</title>
          <description>Previous diagnosis of anxiety disorder</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Spondylopathy</title>
          <description>Previous diagnosis of any spondylopathy</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type 2 Diabetes Mellitus</title>
          <description>Previous diagnosis of type 2 diabetes mellitus</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Other comorbidities</title>
          <description>Previous diagnosis of any other comorbidities</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="32"/>
                    <count group_id="B2" value="33"/>
                    <count group_id="B3" value="65"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention</title>
        <description>Change in Reflux Disease Questionnaire Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 6, with a higher punctuation meaning a worse outcome. Symptom change of ≥ 0,6 points from baseline was considered clinically relevant.</description>
        <time_frame>Primary outcome will be assessed at baseline and 6 weeks after starting each period</time_frame>
        <population>All patients who received the intervention head of bed elevation were grouped, regardless of the arm of the study they came from. Likewise, all participants of any arm who received control intervention were grouped. Only 39 patients who completed both interventions were analyzed because of the crossover nature of this clinical trial.</population>
        <group_list>
          <group group_id="O1">
            <title>Head of Bed Elevation</title>
            <description>Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks.
Head of bed elevation: Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will sleep in a bed without inclination during a first period of 6 weeks.
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Reflux Disease Questionnaire Scores Administered at Baseline and 6 Weeks After Each Intervention</title>
          <description>Change in Reflux Disease Questionnaire Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 6, with a higher punctuation meaning a worse outcome. Symptom change of ≥ 0,6 points from baseline was considered clinically relevant.</description>
          <population>All patients who received the intervention head of bed elevation were grouped, regardless of the arm of the study they came from. Likewise, all participants of any arm who received control intervention were grouped. Only 39 patients who completed both interventions were analyzed because of the crossover nature of this clinical trial.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.2397" spread="1.2236"/>
                    <measurement group_id="O2" value="0.0869" spread="1.2562"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>One tail paired t test.</non_inferiority_desc>
            <p_value>0.0002</p_value>
            <p_value_desc>A priori threshold for statistical significance was 0.05</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.3267</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>2.1604</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6263</ci_lower_limit>
            <ci_upper_limit>2.0270</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>McNemar's chi squared statistic</non_inferiority_desc>
            <p_value>0.0082</p_value>
            <p_value_desc>A priori threshold for statistical significance was 0.05</p_value_desc>
            <method>McNemar</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.3590</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6255</ci_lower_limit>
            <ci_upper_limit>-0.0924</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Quality of Life as Assessed by Short Form 36 Questionnaire, Administered at Baseline and 6 Weeks After Each Intervention</title>
        <description>Change in Short Form 36 Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 100, with a higher punctuation meaning a better outcome. Quality of life change of ≥ 10 points from baseline was considered clinically relevant.</description>
        <time_frame>Secondary outcome will be assessed at baseline and 6 weeks after starting each period</time_frame>
        <population>Patients who received the intervention head of bed elevation were grouped, regardless of the arm of the study they came from. Likewise, all participants of any arm who received control intervention were grouped. For crossover reasons, only 39 patients who completed both interventions were analyzed, and 1 patient was excluded because of missing data</population>
        <group_list>
          <group group_id="O1">
            <title>Head of Bed Elevation</title>
            <description>Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks.
Head of bed elevation: Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>Participants will sleep in a bed without inclination during a first period of 6 weeks.
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Quality of Life as Assessed by Short Form 36 Questionnaire, Administered at Baseline and 6 Weeks After Each Intervention</title>
          <description>Change in Short Form 36 Scores administered at baseline and 6 weeks after each intervention. Range from 0 to 100, with a higher punctuation meaning a better outcome. Quality of life change of ≥ 10 points from baseline was considered clinically relevant.</description>
          <population>Patients who received the intervention head of bed elevation were grouped, regardless of the arm of the study they came from. Likewise, all participants of any arm who received control intervention were grouped. For crossover reasons, only 39 patients who completed both interventions were analyzed, and 1 patient was excluded because of missing data</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5992" spread="19.0268"/>
                    <measurement group_id="O2" value="-0.3139" spread="17.6856"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>One tail paired t test.</non_inferiority_desc>
            <p_value>0.099</p_value>
            <p_value_desc>A priori threshold for statistical significance was 0.05</p_value_desc>
            <method>t-test, 1 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.9131</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>32.5093</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.5987</ci_lower_limit>
            <ci_upper_limit>3.7724</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>McNemar's chi squared statistic</non_inferiority_desc>
            <p_value>0.8084</p_value>
            <p_value_desc>A priori threshold for statistical significance was 0.05</p_value_desc>
            <method>McNemar</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.0263</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.2651</ci_lower_limit>
            <ci_upper_limit>0.2125</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Preference</title>
        <description>Percentage of patients who preferred head of bed elevation after trial ending</description>
        <time_frame>Secondary outcome will be assessed 14 weeks after starting the trial</time_frame>
        <population>All participants who used both head of bed elevation and control interventions, regardless they did not complete the entire trial or did not retrieve all the questionnaires, were asked for their preference between head of bed elevation or control intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants who used both head of bed elevation and control interventions, regardless they did not complete the entire trial or did not retrieve all the questionnaires.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Preference</title>
          <description>Percentage of patients who preferred head of bed elevation after trial ending</description>
          <population>All participants who used both head of bed elevation and control interventions, regardless they did not complete the entire trial or did not retrieve all the questionnaires, were asked for their preference between head of bed elevation or control intervention.</population>
          <units>percent of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.158" lower_limit="50.635" upper_limit="75.681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected over a period of 14 weeks for each participant.</time_frame>
      <desc>The definition of serious adverse event differs from the clinicaltrials.gov definition. In the present study a serious adverse event was the one that led the patient to the suspension of the therapeutic intervention.
Adverse event information were collected during six serial and telephonic interviews for each patient enrolled in the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Head of Bed Elevation</title>
          <description>Participants will sleep with head of bed raised with standard 20 cm-height wooden blocks during a first period of 6 weeks.
Head of bed elevation: Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>Participants will sleep in a bed without inclination during a first period of 6 weeks.
Standard treatment: Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Varicose veins pain</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Cervical pain">Cervical pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Lumbar pain">Lumbar pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title vocab="Bed slipping">Bed slipping</sub_title>
                <description>Participants reported they slip themselves from the surface of the bed, because of bed inclination.</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Bed unsteadiness">Bed unsteadiness</sub_title>
                <description>Patients reported their bed was unstable when using wooden blocks for head of bed elevation</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose veins pain</sub_title>
                <description>Lower limbs pain attributed to local venous insufficiency</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Bed slipping</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="63"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Cervical pain">Cervical pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Lumbar pain">Lumbar pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Knee pain">Knee pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Headache">Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Bed slipping</sub_title>
                <description>Participants reported they slip themselves from the surface of the bed, because of bed inclination.</description>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
              <event>
                <sub_title vocab="Bed unsteadiness">Bed unsteadiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Sexual activity inte">Sexual activity interference</sub_title>
                <description>Patients reported their sexual activity was difficult when using wooden blocks for head of bed elevation</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title vocab="Varicose veins pain">Varicose veins pain</sub_title>
                <description>Lower limbs pain attributed to local venous insufficiency</description>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="63"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="54"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Ivan Mauricio Villamil Morales</name_or_title>
      <organization>Universidad Nacional de Colombia</organization>
      <phone>+573178755369</phone>
      <email>imvillamilm@unal.edu.co</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

